ClinicalTrials.gg
CompletedNCT01625481Updated May 28, 2014

Seal-V Safety and Performance Study

A Phase 1 interventional study of Seal-V in C.Surgical Procedure; Vascular (Peripheral), sponsored by Sealantis Ltd.. Completed at 3 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-28.

Sponsored by Sealantis Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to further assess the safety and performance of Seal-V as an adjunct to standard surgical procedure for achieving hemostasis in patients undergoing peripheral vascular reconstruction surgeries using synthetic grafts.

02

Conditions studied

  • C.Surgical Procedure; Vascular (Peripheral)
03

In context

Lead sponsor

Sealantis Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of >18 years of age
  • Signed
  • Patients requiring vascular reconstruction surgeries using synthetic (such as PTFE, Dacron) or autologous (such as native veins) grafts, including the following:
  • Peripheral bypass surgeries, such as arterio-arterial bypasses [including: axillo-(bi)femoral, ilio-(bi)femoral, femoro-femoral, ilio-popliteal, femoro-popliteal (including below knee), femoro-tibial vessel bypass]
  • Arteriovenous (AV) dialysis access shunt in the upper or lower extremity
  • Patients able and willing to complete all follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Vascular surgery other than peripheral bypass surgeries and arteriovenous (AV) dialysis access shunt procedures as described above
  • Reoperation at the same treatment site
  • Known sensitivity to device materials, such as indigo carmine dye or alginate
  • Pregnant or lactating women
  • Systemic infection
  • Participation in another clinical trial or treatment with any agent in past 30 days
  • Congenital coagulation disorders (e.g., thrombocytopenia [\<100,000 count], thromboasthenia, hemophilia, or von Willebrand disease)
  • Severe congenital or acquired immunodeficiency (e.g., infection or long term treatment with drugs)
  • Prior radiation therapy to the operating field

Intraoperative Exclusion Criteria:

  • Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
  • Intraoperative change in planned surgical procedure that results in the patient no longer meeting preoperative inclusion and/or exclusion criteria
  • Local infection at the operating field
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Seal-V

    A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.

    Device: Seal-V

Interventions

  • DeviceSeal-V

    Seal-V is applied adjunctively to cover the suture lines.

    Also known as: SEAlantis Vascular WP2(A)

06

What researchers measure

Primary outcomes

  1. TTH, Time to Hemostasis

    Duration from the point at which circulation is restored to the graft/artery until bleeding ceases at the treatment site

    Time frame: Perioperative; within 10 minutes after clamp release

Secondary outcomes

  1. Successful cessation of bleeding at a treatment site

    Time frame: Perioperative; within 10 minutes after clamp release

  2. Intraoperative blood loss

    Measured by weighing the surgical swabs used only in the application area and used from the time Seal-V was applied until hemostasis

    Time frame: Perioperative

  3. Incidence of successful deployment of the Seal-V device

    Time frame: Perioperative

07

Study locations

3 sites
  • Department of Vascular Surgery, Bnai-Zion Medical Center
    Haifa, Israel
  • Vascular Surgery Department, Rambam Health Care
    Haifa, Israel
  • Department of Vascular Surgery, Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01625481
Lead sponsor
Sealantis Ltd.
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
Jul 2012
Primary completion
Dec 2013
Completion
Mar 2014
Last update
May 28, 2014

Study contacts

Rina Lev, PhD
study director · Sealantis Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion